May 19 (Reuters) - Prime Medicine Inc PRME.O:
PRIME MEDICINE ANNOUNCES STRATEGIC RESTRUCTURING TO FOCUS ON OPPORTUNITIES IN LARGE GENETIC LIVER DISEASES, CYSTIC FIBROSIS, AND PARTNERED PROGRAMS ALONGSIDE CEO LEADERSHIP TRANSITION
PRIME MEDICINE INC - TO REDUCE HEADCOUNT BY 25%
PRIME MEDICINE INC - ALLAN REINE APPOINTED CEO OF PRIME MEDICINE
PRIME MEDICINE INC - IN ARBITRATION WITH BEAM THERAPEUTICS OVER AATD PROGRAM
PRIME MEDICINE INC: KEITH GOTTESDIENER TO STEP DOWN AS CEO
Source text: ID:nGNX6lhsTJ
Further company coverage: PRME.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.